[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
[3] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[4] |
CAO Weiping, ZHANG Shichao, NI Xia, XIE Bing, WANG Xinzhi, XING Mengtao.
Research Progress in Liver Injury Caused by Drugs Commonly Used during Pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 528-531.
|
[5] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[6] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[7] |
LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli.
Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427.
|
[8] |
ZHOU Yue, LIU Shuo, SONG Haibo.
Roles of licensed pharmacists in drug classification management
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 428-434.
|
[9] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[10] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[11] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[12] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[13] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[14] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
[15] |
YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan.
Comparative study on data set of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.
|